For patients with PI3K mutated metastatic breast cancer who progress on a PI3K inhibitor, will you use an alternative PI3K inhibitor subsequently?

Currently, there is no robust clinical evidence supporting the sequential use of different PI3K inhibitors after progression on a prior PI3K inhibitor. The INAVO120 trial (and CAPItello-291 for capivasertib) excluded patients who had prior treatment with any PI3K, AKT, or mTOR inhibitor, or any agen...